Genmab A (GMAB) Receivables - Other (2023 - 2025)

Genmab A's Receivables - Other history runs 3 years deep, the most recent figure standing at $62.0 million for Q4 2025.

• Quarterly Receivables - Other rose 26.53% year-over-year to $62.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $62.0 million (up 26.53% YoY) and the FY2025 annual result came in at $62.0 million, up 26.53% from the prior year.
• Receivables - Other was $62.0 million for Q4 2025 at Genmab A, up from $49.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $62.0 million in Q4 2025 and bottomed at $43.0 million in Q4 2023.
• A 3-year average of $51.3 million and a median of $49.0 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other grew 13.95% — and 2025, when it gained 26.53%.
• Genmab A's Receivables - Other stood at $43.0 million in 2023, then rose by 13.95% to $49.0 million in 2024, then gained by 26.53% to $62.0 million in 2025.
• Business Quant data shows GMAB's Receivables - Other at $62.0 million in Q4 2025, $49.0 million in Q4 2024, and $43.0 million in Q4 2023.